Hartford, CT5 Active Studies

Ulcerative Colitis Clinical Trials in Hartford, CT

Find 5 actively recruiting ulcerative colitis clinical trials in Hartford, CT. Connect with local research sites and explore new treatment options.

5
Active Trials
4
Sponsors
566
Enrolling

Recruiting Ulcerative Colitis Studies in Hartford

RecruitingHartford, CTNCT04844606

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks ...

150 participants
Eli Lilly and Company
View Study Details
RecruitingHartford, CTNCT04624230

Evaluation of Oral Tofacitinib in Children Aged 2 to 17 Years Old Suffering From Moderate to Severe Ulcerative Colitis

This study, A3921210 is designed to evaluate the efficacy, safety and pharmacokinetics (PK) of tofacitinib in pediatric participants with moderately to severely active UC. In the US and EU, patients w...

120 participants
Pfizer
View Study Details
RecruitingHartford, CTNCT05076175

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participa...

120 participants
Bristol-Myers Squibb
View Study Details
RecruitingHartford, CTNCT03847467

Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy

Randomized, placebo-controlled dose-ranging study of 2'-FL in IBD, Crohn's Disease (CD) and ulcerative colitis (UC). The overarching hypothesis is that 2'-FL supplementation in IBD will be safe and we...

116 participants
Children's Hospital Medical Center, Cincinnati
View Study Details
RecruitingHartford, CTNCT05784246

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Moderately to Severely or Active Ulcerative Colitis

The main purpose of this study is to investigate efficacy, pharmacokinetics and safety of the drug in pediatric participants with moderately to severely active ulcerative colitis (UC)....

60 participants
Eli Lilly and Company
View Study Details

About Ulcerative Colitis Clinical Trials in Hartford

Ulcerative colitis is a chronic inflammatory bowel disease that causes inflammation and ulcers in the innermost lining of the colon and rectum. It typically presents with bloody diarrhea, abdominal pain, and urgency. Treatment includes aminosalicylates, corticosteroids, immunosuppressants, and biologics.

There are currently 5 ulcerative colitis clinical trials recruiting participants in Hartford, CT. These studies are seeking a combined 566 participants. Research is being sponsored by Eli Lilly and Company, Pfizer, Bristol-Myers Squibb and 1 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Ulcerative Colitis Clinical Trials in Hartford — FAQ

Are there ulcerative colitis clinical trials in Hartford?

Yes, there are 5 ulcerative colitis clinical trials currently recruiting in Hartford, CT. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Hartford?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Hartford research site will contact you about next steps.

Are clinical trials in Hartford free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Hartford studies also compensate for your time and travel.

What ulcerative colitis treatments are being tested?

The 5 active trials in Hartford are testing new therapies including novel drugs, biologics, and treatment approaches for ulcerative colitis.

Data updated March 2, 2026 from ClinicalTrials.gov